Searchable abstracts of presentations at key conferences on calcified tissues

ba0006lb1 | (1) | ICCBH2017

Treatment with a Novel activin receptor IIB ligand trap improves muscle mass and bone geometry in a mouse model of severe Osteogenesis Imperfecta

Tauer Josephine T. , Rauch Frank

Objective: Osteogenesis imperfecta (OI) is primarily characterized by bone fragility but is also associated with lower muscle mass and function. As muscle mass and bone mass are closely linked, an intervention that increases muscle mass should also increase bone mass. Here we investigated the effect of a novel activin receptor IIB ligand trap, ACE-2494 (Acceleron Pharma), on skeletal muscle mass and bone properties in a mouse model of severe dominant OI, the Col1a1<su...

ba0007lb1 | (1) | ICCBH2019

Genetic inactivation of osteocalcin in Col1a1Jrt/+ mice, a model of dominant osteogenesis imperfecta, restores glucose metabolism to wild-type levels

Tauer Josephine T , Komarova Svetlana V

Objective: Osteocalcin, an osteoblast-derived hormone, is among the most abundant proteins in bone and is involved in the regulation of whole-body metabolism, muscle adaptation, and reproduction. High bone turnover and low bone mass are clinical hallmarks of Osteogenesis Imperfecta (OI), a bone disease mainly caused by mutations in the collagen-I gene. Recently, we have shown that growing mice with a severe dominant form of OI, Col1a1Jrt/+ mice, displayed significantly elevate...

ba0004oc15 | (1) | ICCBH2015

Osseous side effects on the growing skeleton exerted by tyrosine kinase inhibitor treatment: data observed in pediatric patients with chronic myeloid leukemia in comparison to a juvenile rat model

Tauer Josephine T , Hofbauer Lorenz C , Erben Reinhold G , Suttorp Meinolf

Background: The tyrosine kinase inhibitor (TKI) imatinib is applied as front-line treatment in adult and pediatric patients with chronic myeloid leukemia (CML) in order to selectively inhibit the causative oncogenic BCR-ABL1 tyrosine kinase. However, TKIs exhibit off-target effects on further kinases involved in the regulation of bone metabolism. As consequence, pediatric patients display longitudinal growth retardation while on imatinib treatment. As CML is a rare disease in ...